RESUMO
Background: Hypertension disorder of pregnancy affects up to8% of all gestations. Pregnancy induced Hypertension (PIH) isdefined as hypertension that develops for first time inpregnancy after 20 weeks of gestation. Pathophysiologicalplacental abnormalities are seen consistently by increasingsecretion of hormone Prolactin. Prolactin (PRL) is apolypeptide hormone primarily secreted by the anterior pituitarygland, whose levels increases physiologically duringpregnancy. The imbalance between the isoforms of prolactincauses PIH.Method: The present study was conducted on 50 healthypregnant controls and 50 clinically established pregnancyinduced hypertensive subjects. Serum Prolactin was measuredby Enzyme Linked Fluorescent Assay Method. For analyzingthe Data, Statistical software Epi info was used. The resultswere revealed in mean ± standard deviation. Comparisons ofcases and control groups were done by applying unpaired ttest.Results: Serum Prolactin was significantly higher in pregnancyinduced hypertensive subjects as compared with healthypregnant control subjects.Conclusion: Abnormally high serum Prolactin in PIH Subjectsis a dreaded complication of pregnancy. Serum Prolactinshould be included in routine investigation.
RESUMO
The increased risk of the transmission of HIV is known to be associated with the presence of STIs and despite the presence of the National STI Control Program in India the number of people with STIs remains high. More than 1 million people acquire a STI every day. The true prevalence of STIs can never be known because of inadequate reporting due to secrecy and stigma associated with them and most of them are not even notifiable. Objectives: (1) To study socio-demographic factors of patient's attending STI clinic (2) To assess knowledge of patients about STI/HIV. (3) To assess protective practices of patients towards STIs. Material and Methods: This cross sectional was conducted in STI clinic, PBM hospital, Bikaner from Dec 2014- Jan 2016 using pre-tested and pre-structured questionnaire. The study variables were analyzed using Epi-Info7 software with application of Mean, Proportion and OR, Chi-square. Results: Out of 97 patients 83.5% knew about STIs. 79.4% reported having knowledge about symptoms of STIs and most common symptom reported was itching over genitals and discharge (85.5%). Statistically significant difference was present between male and female patient's knowledge about premarital sex as a factor for acquisition of STIs. 79.3% were using condoms to protect from STIs. The difference was statistically significant between knowledge and practice regarding condom use (χ2 = 6.544, df=1, p=0.01). Statistically significant difference was present between male and female patients practice regarding regular visit to STI clinic. Conclusion: Knowledge of patients regarding protective practices is not matching with their protective behavior.
RESUMO
Management of cardiovascular risk factors in diabetes demands special attention due to their co-existence. Pioglitazone (PIO) and telmisartan (TLM) combination can be beneficial in effective control of cardiovascular complication in diabetes.In this research,we developed and validated a high throughput LC–MS/MS method for simultaneous quantitation of PIO and TLM in rat plasma. This developed method is more sensitive and can quantitate the analytes in relatively shorter period of time compared to the previously reported methods for their individual quantification. Moreover, till date, there is no bioanalytical method available to simultaneously quantitate PIO and TLM in a single run. The method was validated according to the USFDA guidelines for bioanalytical method validation.A linear response of the analytes was observed over the range of 0.005–10μg/mL with satisfactory precision and accuracy. Accuracy at four quality control levels was within 94.27%–106.10%. The intra-and inter-day precision ranged from 2.32% to 10.14% and 5.02% to 8.12%,respectively.The method was reproducible and sensitive enough to quantitate PIO and TLM in rat plasma samples of a preclinical pharmacokinetic study.Due to the potential of PIO-TLM combination to be therapeutically explored,this method is expected to have significant usefulness in future.
RESUMO
Background: Following a drug eruption, patients and their doctors need to know which drugs can be safely administered for subsequent illnesses. Currently available laboratory tests are unable to answer this question in a clinically meaningful manner. Aims: To describe our use of oral provocation tests to provide a list of safe drugs to patients. Methods: We studied the records of 100 patients who underwent oral provocation testing in our department between 2003 and 2009. All patients were admitted to hospital and drugs were administered under supervision, one drug per day. A dermatologist evaluated all symptoms and signs that developed following drug intake. Results: Sixty nine women and 31 men underwent provocation testing. There were 96 reactions in 61 patients, of which 44 reactions in 34 patients were judged to be true reactions. All reactions could be controlled, with treatment or spontaneously. A list of safe drugs was provided to the patient along with written instructions to avoid any drug(s) that had produced a reaction. Conclusions: Oral provocation tests are safe and effective in providing patients with a list of drugs they can take safely. These tests should preferably be undertaken after admitting the patient to hospital.
RESUMO
Background: Some patients report hypersensitivity reactions to many drugs making it difficult to prescribe medications when they fall ill. Aim: To describe the clinical profile of multiple drug hypersensitivity and the results of challenge testing in a large teaching hospital.Methods: We performed a five-year retrospective review of the records of patients who complained of reactions to two or more unrelated drugs and avoided medication because of a fear of developing reactions. Oral challenge testing was carried out in hospital with drugs suspected by the patient to cause reactions and/or commonly prescribed medications. A positive reaction was diagnosed when symptoms and signs resembled previously experienced episodes and there was no such reaction with placebo. Results: Twenty three patients (aged 14-65 years; 19 females) underwent challenge testing. Their complaints had been present for 1-30 years, with 2-40 drug reaction episodes reported. Antibiotics and non-steroidal anti-inflammatory drugs (NSAIDs) were most commonly implicated, and urticaria/angioedema were the most often reported manifestations. The patients underwent 3-27 challenges with 1-24 drugs. Three had positive challenge reactions with various NSAIDs, 13 developed symptoms and signs that were judged not to be true reactions, and 7 had no reactions. None of our patients qualified for a diagnosis of true multiple drug hypersensitivity. Conclusion: Patients who believe they are allergic to multiple, pharmacologically unrelated drugs are usually mistaken. Challenge testing is a reliable way of demonstrating this and providing patients with a list of safe drugs.
RESUMO
Spot blotch resistant (IBON 18) and susceptible (RD 2508) lines were crossed to investigate inheritance of resistance and to identify simple sequence repeats (SSRs) associated with resistance. F1 resistance was intermediate and suggested additive nature of inheritance. Three additive genes was noted in the distribution of F3, F4 and F5 generations. In F6 and F6-7, the quantitative and qualitative approaches also suggested the control of three resistance genes. The parents and the RILs (F6/F6-7) were grown in four environments and spot blotch severity recorded. Forty five SSR primers, specific for chromosomes 1 (7H) and 5 (1H), were applied. Of these, 12 were polymorphic between the parents, and between the resistant and susceptible bulks. Three markers BMS 32, BMS 90 and HVCMA showed association with resistance, which was further confirmed through selective genotyping. The co-segregation data on the molecular markers (BMS 32, BMS 90 and HVCMA) and spot blotch severity on 173 RILs was analyzed by single marker linear regression approach. Significant regression suggested linkage among BMS 32, BMS 90 and HVCMA and the three resistant genes (designated as Rcs-qtl-5H-1, Rcs-qtl-5H-2 and Rcs-qtl-1H-1.) respectively. These markers explained 28 percent, 19 percent and 12 percent of variation respectively, for spot blotch resistance among the RILs.